What does Molbio Diagnostics Limited do?

Molbio Diagnostics Limited is an in-vitro diagnostics company that manufactures portable, battery-operated real-time PCR platforms (Truenat) for rapid point-of-care molecular testing across infectious diseases and oncology.

When does the Molbio Diagnostics IPO open and close?

The IPO opens on 10 August 2026 and closes on 12 August 2026.

What is the price band of the Molbio Diagnostics IPO?

The price band is fixed at ₹768 to ₹807 per equity share.

What is the lot size and minimum investment?

The minimum lot size is 18 shares, requiring a minimum retail investment of ₹14,526 at the upper price band.

What is the total issue size of Molbio Diagnostics IPO?

The total issue size is ₹939.70 crore, consisting of a Fresh Issue of ₹200.00 crore and an Offer for Sale of ₹739.70 crore.

Where will Molbio Diagnostics shares be listed?

The equity shares will be listed on both BSE and NSE Mainboard platforms on 17 August 2026.

IPO Details

Molbio Diagnostics Limited IPO

Apply Now Track All IPOs

Mainboard IPO

₹13,824

Minimum Investment

Exchange Listed · NSE / BSESEBI Regulated Issue

About Company

Company Name: Molbio Diagnostics Limited

Industry / Sector: Healthcare & Diagnostics

Founded Year: 2000

Promoters: Exxora Trading LLP, Dr. Chandrasekhar Bhaskaran Nair

Incorporated in 2000, Molbio Diagnostics Limited is an innovation-driven, point-of-care (POC) medical diagnostics company in India. The company specializes in the development, manufacturing, and commercialization of rapid, accurate, and cost-effective molecular diagnostic platforms (Truenat) for infectious and non-communicable diseases including Tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV.

IPO Basic Details

Company Name	Molbio Diagnostics Limited
IPO Type	Mainboard IPO
Price Band	₹768 – ₹807
Lot Size	18 Shares
Total Issue Size	1,16,46,246 Equity Shares (₹939.70 Cr)

IPO Strengths & Risks

Strengths

Pioneer in battery-operated, portable point-of-care molecular diagnostic solutions
Extensive proprietary Truenat platform capable of testing 30+ diseases via 43 assays
Strong R&D capabilities with 150+ scientific staff and 190+ international patents
Integrated manufacturing facilities across Goa, Bengaluru, Visakhapatnam, and Pune
Strategic expansion into radiology and digital pathology via acquisitions

Risks

Dependence on a limited range of core diagnostic platforms (Truenat system)
Susceptibility to changes in government health procurement programs and policies
High competition within the global in-vitro diagnostics (IVD) market
Strict regulatory compliance and approval timelines across international jurisdictions

IPO Important Dates

IPO Open Date	10 Aug 2026
IPO Close Date	12 Aug 2026
Basis of Allotment	13 Aug 2026
Refund Initiation	14 Aug 2026
Demat Credit Date	14 Aug 2026
Listing Date	17 Aug 2026
Anchor Investor Date	-
UPI Mandate Deadline	-

IPO Objectives

Capital expenditure for machinery and equipment – -
Funding working capital requirements – -
Debt repayment – -
General corporate purposes – Balance Amount

Investor Reservation

QIB Quota	Not more than 50.00% of Net Issue
Retail Quota	Not less than 35.00% of Net Issue
HNI Quota	-
Employee Quota	-
Shareholder Quota	-
Anchor Investor Allocation	-

Market Lot Details

Application	Lot Size	Shares	Amount
Retail Minimum	1 Lot	18	₹14,526
Retail Maximum	13 Lots	234	₹1,88,838
S-HNI Minimum	14 Lots	252	₹2,03,364
S-HNI Maximum	68 Lots	1224	₹9,87,768
B-HNI Minimum	69 Lots	1242	₹10,02,294

Key Performance Indicators (KPI)

ROE	15.59% (Mar 2026) / 16.20% (Mar 2025)
ROCE	17.55% (Mar 2026) / 20.98% (Mar 2025)
RoNW	-
PAT Margin	11.28% (Mar 2026) / 13.48% (Mar 2025)
EBITDA Margin	22.56% (Mar 2026) / 24.97% (Mar 2025)
EPS	₹14.56 (Pre-IPO) / ₹14.24 (Post-IPO)
NAV per share	-
Debt to Equity	0.36 (Mar 2026)
P/E Ratio	-
Industry P/E	-

Company Financial Data

Period	Assets	Total Income	PAT	EBITDA	Net Worth	Borrowings
FY2026 (31 Mar 2026)	₹2,148.42 Cr	₹1,455.17 Cr	₹164.14 Cr	₹328.24 Cr	₹1,144.68 Cr	₹412.64 Cr
FY2025 (31 Mar 2025)	₹1,461.56 Cr	₹1,027.94 Cr	₹138.58 Cr	₹256.64 Cr	₹952.95 Cr	₹123.16 Cr
FY2024 (31 Mar 2024)	₹1,221.06 Cr	₹840.66 Cr	₹83.54 Cr	₹185.09 Cr	₹807.94 Cr	₹174.58 Cr

Grey Market Premium

GMP Price	Pending / TBA
Kostak Rate	Not Available
Subject to Sauda	Not Available
Last Updated	Aug 2026
Estimated Listing Price	TBA

IPO Subscription Data

Total Subscription	Pending
QIB (Ex Anchor)	Pending
HNI Subscription	Pending
Retail Subscription	Pending
Anchor	-

IPO Intermediaries

Registrar: KFin Technologies Limited

Registrar Website: https://kosmic.kfintech.com

IPO Lead Manager(s)

Kotak Mahindra Capital Company Limited

IPO Documents

DRHP RHP Prospectus PDF Investor Presentation

Frequently Asked Questions (FAQ)

Explore More Investment Opportunities

Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.

Insight Hub

Read IPO news, blogs & market insights

→

Unlisted Shares

Invest before public listing

→

Compare Brokers

Find the best broker platform

→